Author

Cong Xu

Observed name: Xu, Cong

Institution: Bethune International Peace Hospital

Observed institutions: Eli Lilly (United States), Yuhuangding Hospital, Otsuka (United States), Bethune International Peace Hospital, Bicycle Therapeutics (United Kingdom), Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Otsuka Pharmaceutical Development & Commercialization, Inc. (United States), Indiana University – Purdue University Indianapolis

ORCID: 0000-0002-3661-0084

Observed ORCID: 0000-0002-3661-0084

OpenAlex ID: A5101624609

Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms

2011 · Wenjie Jessie Lu, Valentina Ferlito, et al. · Chirality · 77

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

2011 · Wenjie Jessie Lu, Cong Xu, et al. · Breast Cancer Research and Treatment · 74

Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo

2012 · Cong Xu, Evan T. Ogburn, et al. · Drug Metabolism and Disposition · 70

In Vitro Analysis and Quantitative Prediction of Efavirenz Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effects on CYPs 2B6, 2C8, 2C9 and 2C19

2013 · Cong Xu, Zeruesenay Desta · Drug Metabolism and Pharmacokinetics · 54

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

2024 · Babar Bashir, Judy S. Wang, et al. · Journal of Clinical Oncology · 30

CYP2B6 Pharmacogenetics–Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling

2013 · Cong Xu, Sara K. Quinney, et al. · Drug Metabolism and Disposition · 28

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes

2016 · Christopher R. Flowers, Luciano J. Costa, et al. · Transplantation and Cellular Therapy · 25

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation

2025 · Capucine Baldini, Loic Verlingue, et al. · Journal of Clinical Oncology · 16

Abstract P4-10-21: Enhanced anti-tumor activity of zelenectide pevedotin in triple negative breast cancer (TNBC) patients (pts) with NECTIN4 gene amplification (amp)

2025 · Niklas Klümper, Viktor Grünwald, et al. · Clinical Cancer Research · 7

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies

2017 · Cong Xu, Timothy K. Goggin, et al. · CPT Pharmacometrics & Systems Pharmacology · 4

High Density of Cancer-Associated Fibroblasts Correlates with Increased Lymphangiogenesis and Poor Prognosis in Hypopharyngeal Carcinoma

2026 · Lanzhen Cui, Cheng Ran, et al. · OncoTargets and Therapy

A Utility Score Framework for Dose Optimization Studies with Binary Efficacy-Safety Endpoints: Sample Size Determination and Bias Characterization

2026 · Gu, Xuemin, Xu, Cong, et al. · arXiv (Cornell University)

Mechanisms and quantitative prediction of Efavirenz metabolism, pharmacogenetics and drug interactions

2013 · Xu, Cong · ProQuest Demo Repository

Works count: 15

Citation count: 385

H-index: 8

I10-index: 8